The Novina Lab received a notice of award for the NIDDK Catalyst award (DP1 mechanism) to study lncRNAs involved in browning of white fat.
The Novina Lab began work on a sponsored research agreement with Atossa Genetics using nanoparticles to reprogram the tumor microenvironment.
Alberto Nobili, Scientist I at Dana-Farber, becomes a Scientific Director at Raqia Therapeutics. Alberto developed the BAT-CAR technology while in the Novina Lab and will lead an effort to translate this technology to benefit patients with cancers.
Bob Distel, Special Advisor and Technology Specialist, formally joined our lab. Bob has been a close Novina Lab collaborator for years, while he worked in BODFI.
Steven Neier, Scientist I at Dana-Farber, accepted a new position with a Dana-Farber Venture Fund called Binney Street Capital, a newly-created fund using the Dana-Farber endowment.
Dorian Dirksen, a third-year medical student at the University of Muenster in Germany, joined the Novina Lab.
Amissi Sadiki, a graduate student from Northeastern University, joined the Novina Lab as a Visiting Scientist.
Breelyn Karno, a postbaccalaureate from the U54 UMass Boston-Dana Farber/Harvard Cancer Center Partnership, joined the Novina Lab.
Raqia Therapeutics begins operations in the Harvard Pagliuca Life Labs. Raqia is a new company based on technology developed in the Novina lab. Clinical advisors include Ken Anderson and Nikhil Munshi, who will help translate the BAT-CAR technology for patients with multiple myeloma.
The Novina Lab began work on two sponsored research agreement with Takeda regarding the platform for detecting RNA-protein interactions.
Novina Lab News